The authors have initiated the process to access DNA from SWOG S0800, a randomized open-label phase II clinical trial that compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense doxorubicin and cyclophosphamide (AC) with nab-paclitaxel followed or preceded by AC as neoadjuvant treatment for HER2-negative locally advanced breast cancer. The gene discussed is ERBB2; the disease is breast cancer.